995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC

Journal article

Peer reviewed

P. Kwo, E. Lawitz, J. McCone, E. Schiff, J. Vierling, D. Pound, M. Davis, J. Galati, S. Gordon, N. Ravendhran, …

Journal of hepatology, Vol.48, pp.S372-S372

2008-01

Metrics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.125 Hepatitis; 1.125.83 HCV
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC
Creators: P. Kwo
E. Lawitz
J. McCone
E. Schiff
J. Vierling
D. Pound
M. Davis
J. Galati
S. Gordon
N. Ravendhran
L. Rossaro
F. Anderson
I. Jacobson
R. Rubin
P. Mukhopadhyay
E. Chaudhri
L. Pedicone
J. Albrecht
Publication Details: Journal of hepatology, Vol.48, pp.S372-S372
Academic Unit: UMMG Dept of Medicine - Hepatology; Leadership Department; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031714247802976